PriceTargets.com logo

Oxford Biomedica - OXB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 433.33
  • Forecasted Upside: 1.96%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 425 As of 12/23/2024 01:29 PM ET
▼ -1.5 (-0.35%)

This chart shows the closing price for OXB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXB

Analyst Price Target is GBX 433.33
▲ +1.96% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 433.33, with a high forecast of GBX 740 and a low forecast of GBX 180. The average price target represents a 1.96% upside from the last price of GBX 425.

This chart shows the closing price for OXB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Oxford Biomedica. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2024Deutsche Bank AktiengesellschaftBoost TargetHoldGBX 250 ➝ GBX 380
5/21/2024Royal Bank of CanadaReiterated RatingOutperformGBX 740
3/20/2024Numis SecuritiesReiterated RatingHoldGBX 180
9/26/2023Liberum CapitalLower TargetHoldGBX 350 ➝ GBX 310
6/21/2023JPMorgan Chase & Co.Reiterated RatingNeutralGBX 495
5/24/2023Royal Bank of CanadaLower TargetOutperformGBX 1,110 ➝ GBX 1,010
10/11/2022Royal Bank of CanadaBoost TargetOutperformGBX 1,020 ➝ GBX 1,110
6/30/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
6/21/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
5/23/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
4/20/2022Liberum CapitalReiterated RatingBuyGBX 1,380
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,340
2/1/2022Royal Bank of CanadaLower TargetOutperformGBX 1,450 ➝ GBX 1,340
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
5/19/2021Liberum CapitalBoost TargetBuyGBX 1,300 ➝ GBX 1,330
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Numis SecuritiesReiterated RatingBuyGBX 1,200
4/15/2021Liberum CapitalReiterated RatingBuyGBX 1,300 ➝ GBX 1,280
4/6/2021Liberum CapitalReiterated RatingBuyGBX 1,280
8/3/2020Liberum CapitalReiterated RatingBuy
7/31/2020Peel HuntReiterated RatingBuy
7/21/2020Peel HuntReiterated RatingBuy
7/21/2020Liberum CapitalReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/24/2020Liberum CapitalLower TargetBuyGBX 1,090 ➝ GBX 1,050
6/19/2020Peel HuntReiterated RatingBuyGBX 1,050 ➝ GBX 1,000
6/8/2020Peel HuntReiterated RatingBuyGBX 1,060 ➝ GBX 1,050
6/8/2020Liberum CapitalReiterated RatingBuy
6/1/2020Peel HuntReiterated RatingBuy
5/29/2020Liberum CapitalReiterated RatingBuy
5/14/2020Jefferies Financial GroupBoost TargetHoldGBX 700 ➝ GBX 730
5/13/2020Peel HuntReiterated RatingBuy
5/13/2020Liberum CapitalReiterated RatingBuy
5/6/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/28/2020Liberum CapitalBoost TargetBuyGBX 860 ➝ GBX 1,090
4/24/2020Peel HuntReiterated RatingBuy
4/8/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/29/2020Liberum CapitalReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalBoost TargetBuyGBX 810 ➝ GBX 860
1/10/2020Peel HuntReiterated RatingBuy
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: GBX 425
Low: 412.50
High: 429

50 Day Range

MA: GBX 415.90
Low: 363.50
High: 445

52 Week Range

Now: GBX 425
Low: 167
High: 450

Volume

417,125 shs

Average Volume

201,698 shs

Market Capitalization

£447.78 million

P/E Ratio

N/A

Dividend Yield

4.57%

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following Wall Street research analysts have issued stock ratings on Oxford Biomedica in the last year: Deutsche Bank Aktiengesellschaft, Numis Securities Ltd, and Royal Bank of Canada.
View the latest analyst ratings for OXB.

What is the current price target for Oxford Biomedica?

0 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. Their average twelve-month price target is GBX 433.33, suggesting a possible upside of 2.0%. Royal Bank of Canada has the highest price target set, predicting OXB will reach GBX 740 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 180 for Oxford Biomedica in the next year.
View the latest price targets for OXB.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OXB, but not buy more shares or sell existing shares.
View the latest ratings for OXB.

What other companies compete with Oxford Biomedica?

Other companies that are similar to Oxford Biomedica include Oxford Nanopore Technologies, Genus, Ergomed, Silence Therapeutics and PureTech Health. Learn More about companies similar to Oxford Biomedica.

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company's listed phone number is +44-1865-783000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. Learn More about contacing Oxford Biomedica investor relations.